Making every risk conversation personal
AREXVY (respiratory syncytial virus vaccine recombinant, adjuvanted)
SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen (AS01B adjuvanted vaccine)
Join the upcoming education webinar with Dr Rodney Pearce and Ms Philippa Holland to explore the burden of respiratory syncytical virus (RSV) and shingles in older adults.
Learning Objectives
RSV learning objectives
- Identify older adults who are eligible for RSV vaccination
- Educate patients on their individual risk of RSV disease and the efficacy and safety profile of AREXVY
- Vaccinate with confidence by learning practical steps to administer AREXVY in everyday practice
Shingles learning objectives
- Understand the risk and impact of shingles
- Recognise the importance of vaccinating adults ≥50 years of age
- Describe the clinical profile of SHINGRIX
- Develop strategies for implementing SHINGRIX discussions within your practice
Agenda
- 7:00 PM AEST – Introduction
- 7:05 PM AEST – RSV presentation
- 7:25 PM AEST – Shingles presentation
- 7:45 PM AEST – Vaccination implementation
- 8:10 PM AEST – Q&A
- 8:30 PM AEST – Close